---
document_datetime: 2025-12-29 11:29:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/aquipta.html
document_name: aquipta.html
version: success
processing_time: 0.104102
conversion_datetime: 2025-12-30 01:51:58.05091
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Aquipta

[RSS](/en/individual-human-medicine.xml/67699)

##### Authorised

This medicine is authorised for use in the European Union

atogepant Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Aquipta](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Aquipta is a medicine used to prevent migraines in adults who have migraines at least 4 days a month.

Aquipta contains the active substance atogepant.

Expand section

Collapse section

## How is Aquipta used?

Aquipta is available as tablets to be taken by mouth once a day. It can only be obtained with a prescription.

For more information about using Aquipta, see the package leaflet or contact your doctor or pharmacist.

## How does Aquipta work?

The exact way that Aquipta works is not fully understood. The active substance in Aquipta, atogepant, attaches to receptors (targets) for proteins called CGRP and amylin-1. These proteins are involved in the development of migraine. By attaching to these receptors, the medicine prevents CGRP and amylin-1 from binding to them. This helps prevent migraines from occurring.

## What benefits of Aquipta have been shown in studies?

Aquipta was shown to reduce the number of days patients have migraines in two main studies.

In one study involving 882 patients who experienced at least 4 migraines a month, treatment with Aquipta for 12 weeks reduced migraines from around 8 days a month to around 3 to 4 days a month, compared with around 5 days for patients taking placebo (a dummy treatment).

In another study involving 760 patients who experienced at least 15 headache days a month with 8 out of these being migraine days, treatment with Aquipta for 12 weeks reduced migraines from around 19 days a month to around 12 days a month, compared with 14 days for patients taking placebo.

## What are the risks associated with Aquipta?

For the full list of side effects and restrictions with Aquipta, see the package leaflet.

The most common side effects with Aquipta (which may affect up to 1 in 10 people) include nausea (feeling sick), constipation, tiredness, somnolence (sleepiness), decreased appetite and decreased weight.

## Why is Aquipta authorised in the EU?

Aquipta can reduce the number of days patients have migraines. Most of the side effects are mild or moderate in severity. Following concerns about a possible link to liver injury, an in-depth safety analysis provided reassurance about the medicine's liver safety profile. The European Medicines Agency therefore decided that Aquipta's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Aquipta?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Aquipta have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Aquipta are continuously monitored. Suspected side effects reported with Aquipta are carefully evaluated and any necessary action taken to protect patients.

## Other information about Aquipta

Aquipta received a marketing authorisation valid throughout the EU on 11 August 2023.

Aquipta : EPAR - Medicine Overview

Reference Number: EMA/361998/2023

English (EN) (116.53 KB - PDF)

**First published:** 25/08/2023

[View](/en/documents/overview/aquipta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-664)

български (BG) (127.29 KB - PDF)

**First published:**

25/08/2023

[View](/bg/documents/overview/aquipta-epar-medicine-overview_bg.pdf)

español (ES) (106.65 KB - PDF)

**First published:**

25/08/2023

[View](/es/documents/overview/aquipta-epar-medicine-overview_es.pdf)

čeština (CS) (128.08 KB - PDF)

**First published:**

25/08/2023

[View](/cs/documents/overview/aquipta-epar-medicine-overview_cs.pdf)

dansk (DA) (106.24 KB - PDF)

**First published:**

25/08/2023

[View](/da/documents/overview/aquipta-epar-medicine-overview_da.pdf)

Deutsch (DE) (109.43 KB - PDF)

**First published:**

25/08/2023

[View](/de/documents/overview/aquipta-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.25 KB - PDF)

**First published:**

25/08/2023

[View](/et/documents/overview/aquipta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (131.2 KB - PDF)

**First published:**

25/08/2023

[View](/el/documents/overview/aquipta-epar-medicine-overview_el.pdf)

français (FR) (103.75 KB - PDF)

**First published:**

25/08/2023

[View](/fr/documents/overview/aquipta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (124.39 KB - PDF)

**First published:**

25/08/2023

[View](/hr/documents/overview/aquipta-epar-medicine-overview_hr.pdf)

italiano (IT) (105.39 KB - PDF)

**First published:**

25/08/2023

[View](/it/documents/overview/aquipta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (134.25 KB - PDF)

**First published:**

25/08/2023

[View](/lv/documents/overview/aquipta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (130.44 KB - PDF)

**First published:**

25/08/2023

[View](/lt/documents/overview/aquipta-epar-medicine-overview_lt.pdf)

magyar (HU) (127.08 KB - PDF)

**First published:**

25/08/2023

[View](/hu/documents/overview/aquipta-epar-medicine-overview_hu.pdf)

Malti (MT) (130.41 KB - PDF)

**First published:**

25/08/2023

[View](/mt/documents/overview/aquipta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (106.68 KB - PDF)

**First published:**

25/08/2023

[View](/nl/documents/overview/aquipta-epar-medicine-overview_nl.pdf)

polski (PL) (130.53 KB - PDF)

**First published:**

25/08/2023

[View](/pl/documents/overview/aquipta-epar-medicine-overview_pl.pdf)

português (PT) (104.07 KB - PDF)

**First published:**

25/08/2023

[View](/pt/documents/overview/aquipta-epar-medicine-overview_pt.pdf)

română (RO) (123.18 KB - PDF)

**First published:**

25/08/2023

[View](/ro/documents/overview/aquipta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (124.48 KB - PDF)

**First published:**

25/08/2023

[View](/sk/documents/overview/aquipta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (126.02 KB - PDF)

**First published:**

25/08/2023

[View](/sl/documents/overview/aquipta-epar-medicine-overview_sl.pdf)

Suomi (FI) (101.51 KB - PDF)

**First published:**

25/08/2023

[View](/fi/documents/overview/aquipta-epar-medicine-overview_fi.pdf)

svenska (SV) (105.71 KB - PDF)

**First published:**

25/08/2023

[View](/sv/documents/overview/aquipta-epar-medicine-overview_sv.pdf)

Aquipta : EPAR - Risk Management Plan

English (EN) (598.95 KB - PDF)

**First published:** 25/08/2023

**Last updated:** 28/06/2024

[View](/en/documents/rmp/aquipta-epar-risk-management-plan_en.pdf)

## Product information

Aquipta : EPAR - Product Information

English (EN) (228.97 KB - PDF)

**First published:** 25/08/2023

**Last updated:** 19/06/2025

[View](/en/documents/product-information/aquipta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-567)

български (BG) (301.65 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/bg/documents/product-information/aquipta-epar-product-information_bg.pdf)

español (ES) (232.72 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/es/documents/product-information/aquipta-epar-product-information_es.pdf)

čeština (CS) (286.63 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/cs/documents/product-information/aquipta-epar-product-information_cs.pdf)

dansk (DA) (236.84 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/da/documents/product-information/aquipta-epar-product-information_da.pdf)

Deutsch (DE) (244.46 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/de/documents/product-information/aquipta-epar-product-information_de.pdf)

eesti keel (ET) (239.42 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/et/documents/product-information/aquipta-epar-product-information_et.pdf)

ελληνικά (EL) (289.57 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/el/documents/product-information/aquipta-epar-product-information_el.pdf)

français (FR) (269.74 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/fr/documents/product-information/aquipta-epar-product-information_fr.pdf)

hrvatski (HR) (276.63 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/hr/documents/product-information/aquipta-epar-product-information_hr.pdf)

íslenska (IS) (240.56 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/is/documents/product-information/aquipta-epar-product-information_is.pdf)

italiano (IT) (252.95 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/it/documents/product-information/aquipta-epar-product-information_it.pdf)

latviešu valoda (LV) (271.36 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/lv/documents/product-information/aquipta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (276.1 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/lt/documents/product-information/aquipta-epar-product-information_lt.pdf)

magyar (HU) (279.78 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/hu/documents/product-information/aquipta-epar-product-information_hu.pdf)

Malti (MT) (292.35 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/mt/documents/product-information/aquipta-epar-product-information_mt.pdf)

Nederlands (NL) (233.8 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/nl/documents/product-information/aquipta-epar-product-information_nl.pdf)

norsk (NO) (232.18 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/no/documents/product-information/aquipta-epar-product-information_no.pdf)

polski (PL) (293.91 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/pl/documents/product-information/aquipta-epar-product-information_pl.pdf)

português (PT) (235.46 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/pt/documents/product-information/aquipta-epar-product-information_pt.pdf)

română (RO) (275.08 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/ro/documents/product-information/aquipta-epar-product-information_ro.pdf)

slovenčina (SK) (285.56 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/sk/documents/product-information/aquipta-epar-product-information_sk.pdf)

slovenščina (SL) (269.62 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/sl/documents/product-information/aquipta-epar-product-information_sl.pdf)

Suomi (FI) (239.71 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/fi/documents/product-information/aquipta-epar-product-information_fi.pdf)

svenska (SV) (230.2 KB - PDF)

**First published:**

25/08/2023

**Last updated:**

19/06/2025

[View](/sv/documents/product-information/aquipta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0008 08/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Aquipta : EPAR - All authorised presentations

English (EN) (39.73 KB - PDF)

**First published:** 25/08/2023

[View](/en/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-733)

български (BG) (35.27 KB - PDF)

**First published:**

25/08/2023

[View](/bg/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_bg.pdf)

español (ES) (33.55 KB - PDF)

**First published:**

25/08/2023

[View](/es/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.16 KB - PDF)

**First published:**

25/08/2023

[View](/cs/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (34.69 KB - PDF)

**First published:**

25/08/2023

[View](/da/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (34 KB - PDF)

**First published:**

25/08/2023

[View](/de/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.39 KB - PDF)

**First published:**

25/08/2023

[View](/et/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (35.81 KB - PDF)

**First published:**

25/08/2023

[View](/el/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_el.pdf)

français (FR) (40.52 KB - PDF)

**First published:**

25/08/2023

[View](/fr/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (33.32 KB - PDF)

**First published:**

25/08/2023

[View](/hr/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (33.53 KB - PDF)

**First published:**

25/08/2023

[View](/is/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (34.04 KB - PDF)

**First published:**

25/08/2023

[View](/it/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.91 KB - PDF)

**First published:**

25/08/2023

[View](/lv/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.61 KB - PDF)

**First published:**

25/08/2023

[View](/lt/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (34.64 KB - PDF)

**First published:**

25/08/2023

[View](/hu/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (40.08 KB - PDF)

**First published:**

25/08/2023

[View](/mt/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (33.68 KB - PDF)

**First published:**

25/08/2023

[View](/nl/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (33.68 KB - PDF)

**First published:**

25/08/2023

[View](/no/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.47 KB - PDF)

**First published:**

25/08/2023

[View](/pl/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_pl.pdf)

português (PT) (40.51 KB - PDF)

**First published:**

25/08/2023

[View](/pt/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.51 KB - PDF)

**First published:**

25/08/2023

[View](/ro/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.88 KB - PDF)

**First published:**

25/08/2023

[View](/sk/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (39.94 KB - PDF)

**First published:**

25/08/2023

[View](/sl/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (33.54 KB - PDF)

**First published:**

25/08/2023

[View](/fi/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (33.61 KB - PDF)

**First published:**

25/08/2023

[View](/sv/documents/all-authorised-presentations/aquipta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Aquipta Active substance atogepant International non-proprietary name (INN) or common name atogepant Therapeutic area (MeSH) Migraine Disorders Anatomical therapeutic chemical (ATC) code N02CD07

### Therapeutic indication

Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month

## Authorisation details

EMA product number EMEA/H/C/005871

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

AbbVie Deutschland GmbH &amp; Co. KG

Knollstrasse 67061 Ludwigshafen Germany

Opinion adopted 22/06/2023 Marketing authorisation issued 11/08/2023 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Aquipta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (155.47 KB - PDF)

**First published:** 28/06/2024

**Last updated:** 19/06/2025

[View](/en/documents/procedural-steps-after/aquipta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Aquipta : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/CHMP/326142/2023

English (EN) (5.41 MB - PDF)

**First published:** 25/08/2023

[View](/en/documents/assessment-report/aquipta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Aquipta

Adopted

Reference Number: EMA/CHMP/257716/2023

English (EN) (119.86 KB - PDF)

**First published:** 23/06/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-aquipta_en.pdf)

#### News on Aquipta

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023) 23/06/2023

**This page was last updated on** 19/06/2025

## Share this page

[Back to top](#main-content)